Cargando…
Significance of monitoring vascular endothelial growth factor, monocyte chemoattractant protein-1 and Interleukin-8 in diabetic macular edema towards early identification of nonresponders to ranibizumab therapy
PURPOSE: Identification of nonresponders prior to anti-vascular endothelial growth factor (anti-VEGF) therapy would help in the judicious clinical management of diabetic macular edema (DME) patients. Thus, a systematic study was initiated to identify nonresponding DME patient population undergoing r...
Autores principales: | Xavier, Tessy, Pallikara, Swetha, Saji, Neha, Radhakrishnan, Natasha, Menon, Krishnakumar N, Pillai, Gopal S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8302316/ https://www.ncbi.nlm.nih.gov/pubmed/34011723 http://dx.doi.org/10.4103/ijo.IJO_3109_20 |
Ejemplares similares
-
Effect of dexamethasone implant on intraocular cytokines in diabetic macular edema
por: Pillai, Gopal S, et al.
Publicado: (2023) -
One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders
por: Salimi, Ali, et al.
Publicado: (2021) -
Diabetic papillopathy with macular edema treated with intravitreal ranibizumab
por: Kim, Moosang, et al.
Publicado: (2013) -
Critical appraisal of ranibizumab in the treatment of diabetic macular edema
por: Stewart, Michael W
Publicado: (2013) -
Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema
por: Demircan, Ali, et al.
Publicado: (2018)